<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02313207</url>
  </required_header>
  <id_info>
    <org_study_id>CLE-IBS-2</org_study_id>
    <nct_id>NCT02313207</nct_id>
  </id_info>
  <brief_title>Confocal Laser Endomicroscopy in IBS Patients</brief_title>
  <official_title>Confocal Endomicroscopy for the Detection of Food Intolerances in Patients With IBS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess dynamic effects of two major antigens on the duodenal mucosa by
      confocal laser endomicroscopy (CLE). Patients will be blinded to the antigens used (wheat,
      yeast). Following CLE it is planned to have a cross over exclusion diet with/without the
      antigens including a washout phase. Furthermore, patients will undergo a 2 week FODMAP diet
      to be able to compare results found of both diets and allow to understand whether our
      findings of food intolerance will be better and more precise than a common FODMAP diet.

      Post CLE food challenge patients biopsies will be taken for histology. They will then be
      randomized into two groups and blinded to the diet they undergo. They will be provided with a
      supply of custom-made bread they will have for 2 weeks (custom made by a bakery in Kiel). For
      one study arm bread will contain either wheat and yeast, for the other arm the bread will not
      contain these ingredients. The taste of the &quot;normal&quot; bread will be denaturised. Crossover
      will take place after a two-week washout phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of mucosal reaction on allergen exposure</measure>
    <time_frame>up to 5 sec</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>IBS</condition>
  <condition>Food Intolerance</condition>
  <arm_group>
    <arm_group_label>FODMAP diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FODMAP diet for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Specific bread diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Specific bread diet eliminating wheat and yeast for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FODMAP</intervention_name>
    <description>patients will undergo a specific FODMAP diet for a period of 2 weeks.</description>
    <arm_group_label>FODMAP diet</arm_group_label>
    <arm_group_label>Specific bread diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        IBS according to the Rome III criteria moderate/severe refractory daily symptoms &gt;1year
        (FGID-C1) sub classified as IBS-D, constipation predominant (IBS-C) or mixed type (IBS-M)
        no past infection to trigger symptom no structural/ biochemical cause of their symptoms
        identified negative gastroscopy, colonoscopy including histology Worsening symptoms after
        meals various exclusion diets - ineffective females not menstruating during CLE no known
        allergy to methylene blue or fluorescein Age &gt;18 years Negative routine testing for food
        intolerance (or known lactose/fructose intolerance) Positive informed consent

        Exclusion Criteria:

        no consent known reason for the abdominal pain and bloating other than lactose/fructose
        intolerance M. Whipple Known infectious gastrointestinal disease Stricture in the upper
        gastrointestinal tract Age &lt;18years Impaired renal function (Creatinine &gt;1.2 mg/dL)
        Pregnancy or breast-feeding Inability to obtain informed consent Active GI Bleeding Known
        allergy to Methylene blue or Fluorescein Participation in other clinical trials within the
        last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annette Fritscher-Ravens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Ellrichmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annette Fritscher-Ravens, MD, PhD</last_name>
    <phone>00494315972075</phone>
    <email>fri.rav@btopenworld.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Ellrichmann, MD</last_name>
    <phone>00494315972075</phone>
    <email>mark.ellrichmann@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Schleswig Holstein, Campus Kiel, Unit Experimental Endoscopy</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Fritscher-Ravens, Prof. Dr.</last_name>
      <phone>00494315972311</phone>
      <email>fri.rav@btopenworld.com</email>
    </contact>
    <contact_backup>
      <last_name>Mark Ellrichmann, MD</last_name>
      <phone>00494315971358</phone>
      <email>mark.ellrichmann@uk-sh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Annette Fritscher-Ravens, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Ellrichmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Mark Ellrichmann</investigator_full_name>
    <investigator_title>Senior Consultant, Unit of Experimental Endoscopy</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

